Dossier assessment
Selpercatinib (RET fusion-positive NSCLC, first line) - Benefit assessment according to § 35a Social Code Book V (expiry of the limitation period)
Report documents
-
Extract of dossier assessment
Selpercatinib (RET fusion-positive NSCLC, first line) - Benefit assessment according to § 35a Social Code Book V (expiry of the limitation period)
-
Dossier assessment
Selpercatinib (RET fusion-positive NSCLC, first line) - Benefit assessment according to § 35a Social Code Book V (expiry of the limitation period)
Drug assessment at a glance
-
Drug assessment at a glance
Selpercatinib (RET fusion-positive NSCLC, first line) - Benefit assessment according to § 35a Social Code Book V (expiry of the limitation period)
Dossier assessment
Adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor
- Patients with PD-L1 expression ≥ 50% of tumour cells; first line therapy: added benefit not proven
- Patients with PD-L1 expression < 50% of tumour cells; first line therapy: added benefit not proven
Project details
- Project no.
- A25-159
- Commission
- Commission awarded on 01.01.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-159
Connected Projects
-
Dossier assessment
Selpercatinib (RET mutant medullary thyroid cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (advanced NSCLC with RET fusion) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET-mutant medullary thyroid cancer, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET fusion-positive thyroid cancer, from 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET fusion-positive solid tumours, from 2 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed